REG - Cambridge Cognition - New £750,000 digital health contract

Cambridge Cognition HoldingsAnnouncement

07/10/2020 07:00

RNS Number : 2986B
  
Cambridge Cognition Holdings PLC
  
07 October 2020
  
 

 
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
 
New £750,000 digital health contract 
 
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a new contract providing cognitive tests and electronic clinical outcome assessments (eCOA) for an Alzheimer's trial (the "Contract"). The total Contract is worth approximately £750,000 over two years, with a considerable proportion of the revenue for the Company expected to be received in 2021. 
 
Alzheimer's trials have seen significant disappointments in recent years, so this pharmaceutical client is taking a new approach with a cutting-edge part-virtual clinical trial which combines in-person and remote testing. Cambridge Cognition is in a unique position to support the delivery of this trial with expertise in both gold-standard cognitive assessment and innovative digital health solutions for frequent, remote testing. 
 
To establish the cognitive impact of the drug, patients will complete CANTABTM cognitive assessments both in clinic and at home. The Company will also capture the important caregiver perspective by deploying an engaging mobile application. To deliver the Contract, Cambridge Cognition will configure existing modules developed for previous clinical trials rather than undertaking bespoke software development.
 
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
"We are delighted to be supporting the continuing pursuit of a new Alzheimer's therapeutic with all three of our major commercial solutions: CANTAB™ cognitive assessments, eCOA questionnaires, and digital health applications. The disease burden for caregivers and family members cannot be overlooked and so we are particularly excited to play such an active role in capturing their experience for the trial." 
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')
 
For further information, contact: 
 



Cambridge Cognition Holdings PLC
Matthew Stork, Chief Executive Officer
Nick Walters, Chief Financial Officer 


Tel: 012 2381 0700
press@camcog.com




finnCap Ltd (NOMAD and Joint Broker)
Geoff Nash / Simon Hicks
Alice Lane / Manasa Patil


Tel: 020 7220 0500
(Corporate Finance)
(Corporate Broking)




Dowgate Capital Limited (Joint Broker)
David Poutney / James Serjeant


Tel: 020 3903 7715
 




IFC Advisory Ltd (Financial PR and IR)
Tim Metcalfe / Graham Herring / Zach Cohen


Tel: 020 3934 6630
 



 
Notes to Editors
 
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
 
For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
CNTBRBDGGUGDGGL